RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
  Inflammatory Bowel Disease
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
IBS Channel

subscribe to IBS newsletter
Latest Research : Gastroenterology : IBS

   EMAIL   |   PRINT
Genome wide approach to pinpoint gene activations in IBD

Aug 23, 2005 - 9:02:00 PM
This study highlights how complex the underlying disease process is in these two diseases, but also indicates some possible future avenues for research of such diseases in general.

[RxPG] In a paper published in PLoS Medicine researchers from the German Genome Research Network have analysed the expression of thousands of genes from patients with inflammatory bowel disease (ulcerative colitis and Crohn disease) using a genome wide approach to produce a comprehensive picture of which genes are activated in these conditions.

Using microarrays¡Xa technique in which thousands of markers for genes are placed together on a silicon chip¡Xthe researchers led by Stefan Schreiber were able to assess whether genes from patients with these two diseases were switched on or off in samples taken from the affected gut. What they found was that 650 genes differed in how active they were between normal individuals and patients with either of the diseases. Interestingly, down-regulation leading to a lack of function was the prevailing pattern the researchers found. In Crohn disease, approximately 84% of differentially expressed genes were found to be less active compared with 42% of the differentially expressed genes in ulcerative colitis. However, none of the 122 differentially expressed genes in Crohn Disease and ulcerative colitis was overexpressed in one disease and underexpressed in the other, which supports the idea of a shared underlying inflammatory process going on in both diseases. This notion is also supported by recent clinical developments that demonstrate that therapies are often applicable to both diseases.

In a second part of the study, the team looked closely at what patterns of gene expression there were; they found that there were changes in many genes associated with abnormal immune response in both diseases; and in ulcerative colitis they found changes in genes responsible for cell growth and proliferation.

Ulcerative colitis and Crohn disease are common chronic relapsing diseases; in the UK, for example, together they affect about one person in every 400, amounting to a total of 120,000 cases of ulcerative colitis and 60,000 of Crohn disease, with 6,000 new cases of ulcerative colitis and 3,000 new cases of Crohn disease every year. Current estimates are of more than 1 million cases each in the US and Europe.

This study highlights how complex the underlying disease process is in these two diseases, but also indicates some possible future avenues for research of such diseases in general.

Publication: Citation: Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, et al. (2005) Dissection of the inflammatory bowel disease transcrptome using genome-wide cDNA microarrays. PLoS Med 2(8): e199.
On the web: www.plosmedicine.org 

Advertise in this space for $10 per month. Contact us today.

Related IBS News
Exercise, eating right could ease IBS, diarrhea and constipation
Budesonide Prolongs Remission of Crohn's Disease
Genome wide approach to pinpoint gene activations in IBD
Certolizumab Shows Significant Benefit in Moderate to Severe Crohn’s Disease
Pediatric Researchers Collaborate to Build Largest Inflammatory Bowel Disease Registry
Irritable bowel syndrome, frequent indigestion common in people with insomnia

Subscribe to IBS Newsletter

Enter your email address:

 Additional information about the news article
All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere¡Xto read, download, redistribute, include in databases, and otherwise use¡Xsubject only to the condition that the original authorship and source are properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)